17000-57-6

Basic information

• Product Name: (7alpha,11beta,17beta)-11,17-dihydroxy-7,17-dimethylandrost-4-en-3-one
• CAS NO: 17000-57-6
• Molecular Formula: C₂₁H₃₂O₃
• Molecular Weight: 332.477
• Mol File: 17000-57-6.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 480.4°C at 760 mmHg
• Flash Point: 258.5°C
• Density: 1.15g/cm³
• Vapor Pressure: 3.01E-11mmHg at 25°C
• Refractive Index: 1.566
• CAS DataBase Reference: (7alpha,11beta,17beta)-11,17-dihydroxy-7,17-dimethylandrost-4-en-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: (7alpha,11beta,17beta)-11,17-dihydroxy-7,17-dimethylandrost-4-en-3-one(17000-57-6)
• EPA Substance Registry System: (7alpha,11beta,17beta)-11,17-dihydroxy-7,17-dimethylandrost-4-en-3-one(17000-57-6)

Safety Data

• Hazardous Substances Data: 17000-57-6(Hazardous Substances Data)

Usage

General Description

"(7alpha,11beta,17beta)-11,17-dihydroxy-7,17-dimethylandrost-4-en-3-one" is a synthetic chemical compound with a molecular formula of C21H34O3. It is a derivative of the hormone testosterone and belongs to the class of androgens, which are male sex hormones. (7alpha,11beta,17beta)-11,17-dihydroxy-7,17-dimethylandrost-4-en-3-one is used in the research and development of pharmaceuticals and has potential applications in the treatment of hormonal imbalances and related disorders. Its chemical structure includes two hydroxyl groups at positions 11 and 17, and two methyl groups at positions 7 and 17. The compound's specific configuration and functional groups make it an important intermediate in the synthesis of various steroid compounds.

Upstream product

• 1043-10-3 11β-hydroxy-17α-methyltestosterone 
• 17021-22-6 11β,17β-dihydroxy-17α-methyl-androsta-4,6-dien-3-one 
• 75-16-1 methylmagnesium bromide 

Relevant articles and documents

ANDROGEN AS A MALE CONTRACEPTIVE AND NON-CONTRACEPTIVE ANDROGEN REPLACEMENT

The present invention relates to methods of providing male contraception using a specified androgen without the need of a separate sterilizing agent. The invention also describes methods for non-contraceptive androgen replacement and devices useful for carrying out both processes.

Method for androgen supplementation

A particular group of androgens is not metabolized to their 5α-reduced form in the prostate and other tissues. Thus, administration of these compounds--testosterone derivatives with a non-hydrogen substituent in the 6α or 7α position--allows one to provide androgen supplementation therapy without stimulating abnormal prostate growth. A preferred compound for use in the invention is 7α-methyl-19-nortestosterone.